Analysis of adjuvant treatment in postmenopausal patients with stage II invasive breast carcinoma - A pattern of care study and quality assurance of 431 consecutive patients in Oslo 1980-1989

Acta Oncologica

Volumn 36, Issue 3, 1997, Pages 255-260

  Raabe, Nils K ^a   Kaaresen, Rolf ^b   Fosså, Sophie D ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0031006785     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869709001259     Document Type: Article

References (19)

1. Nolvadex Adjuvant Trial Organisation (NATO). Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983: 450.
2. Nolvadex Adjuvant Trial Organisation (NATO). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Analysis at eight years. Adjuvant Trial Organisation. Br J Cancer 1988; 57: 608-11.
3. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Report from the Breast Cancer Trials Comittee. Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987: 171-5.
4. Henderson IC, Mouridsen H. Early breast cancer trialists' collaborative group (EBCTCG). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28896 women. N Engl J Med 1988; 319: 1681-92.
5. Consensus Conference. National Institute of Health. Adjuvant therapy for breast cancer. JAMA 1985, 254: 3461-3.
6. Cancer mammae. Primary treatment. Norwegian Cancer Society. Norwegian Surgical Association. 1st edition. Oslo, 1981.
7. Cancer mammae. Primary treatment. Norwegian Cancer Society. Norwegian Surgical Association. Norwegian Association of Therapeutic Oncology. 2nd edition. Oslo, 1988.
8. Raabe NK, Fossa SD. Primary invasive breast carcinoma in Oslo 1980 89. Incidence and delay. Acta Oncol 1996; 35: 9-15.
9. Gundersen S, Hannisdal E, Soreide JA, Skarstein A, Varhaug JE. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: A randomized study. Breast Cancer Res Treat 1995, 36: 49-53.
10. Cody HS, Laughlin EH, Trillo C, Urban JA. Have changing treatment patterns affected outcome for operable breast cancer? Ten-year follow-up in 1288 patients, 1965 to 1978. Ann Surg 1991; 213: 297-307.
11. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Early breast cancer trialists' collaborative group. Lancet 1992, 339: 1-15.
12. Ovarian ablation in early breast cancer: An overview of the randomised trials. Early breast cancer trialist's collaborative group. Lancet 1996, (in press).
13. Carbone P. Adjuvant therapy of stage II breast cancer. Cancer 1990; 65: 2148-54.
14. Auquier A, Rutqvist LE, Høst H, Rotstein S, Arriagda R. Post-mastectomy megavoltage radiotherapy: The Oslo and Stockholm trials. Eur J Cancer 1992, 28: 433-7.
15. Effects of radiotherapy and surgery in early breast cancer. Early breast cancer trialists' collaborative group. N Engl J Mcd 1995; 333: 1444-55.
16. Rutqvist LE, Cedermark B, Glas U, et al. Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Acta Oncol 1992; 312: L265-70.
17. Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast canter: Long-term follow-up and causes of death. J Clin Oncol 1993; 11: 29-35.
18. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early-stage breast cancer: Effect on intercurrent morbidity and mortality. J Clin Oncol 1991; 9: 1740-8.
19. Hand R, Sener S, Imperato J, Chmiel JS, Sylvester JA, Fremgen A. Hospital variables associated with quality of care for breast cancer patients. JAMA 1991, 266: 3429-32.